Best Month-to-Month Tirzepatide Plans

How this ranking is produced

The sort key is stated in the title and applied to the dataset. Nothing is weighted by hand, no programme pays for position, and the underlying figures are downloadable from the price index so the order can be reproduced rather than trusted. Where a programme is excluded, it is because it fails the criterion, not because of an editorial judgement about it.

What this ranking cannot tell you

Whether shipments arrive on time, whether messages get answered, or whether the clinical oversight is adequate. We hold no measurements of those we would defend, so they are absent rather than estimated. Read the individual review and run the pharmacy checks before enrolling anywhere this list surfaces.

How wide the spread actually is

Between the top and bottom of this list the difference is $382 on the criterion being ranked. NexLife leads and LifeMD sits last among those that qualify, for the identical molecule from the same category of licensed pharmacy.

That spread is not explained by the medicine. It is overhead, clinical wrap, pharmacy sourcing, marketing cost and margin. Knowing that is what makes shopping this category worthwhile at all: there is real money on the table and no clinical reason to leave it there.

What this ranking deliberately ignores

Shipping reliability, response times, clinical depth and how a programme behaves when something goes wrong. We hold no measurements of those we would defend, so they are absent rather than estimated, and no weighting has been applied to smuggle a judgement about them into the order.

That makes this list narrower than an editorial round-up and considerably harder to dispute. It answers one question exactly, and it says which question in the title.

Using a ranking without being misled by one

Set the dose you expect to maintain on, filter to prices we verified at source, and read the individual review of anything in the top three before enrolling. A ranking is a shortlist generator, not a recommendation, and the differences that decide satisfaction are mostly not the ones a ranking can measure.

Then re-run it annually. Programmes move pricing without telling existing patients, and several tracked programmes changed rates more than once in the past year.

The comparison most people get wrong

Almost every published tirzepatide ranking sorts on advertised entry price. That figure describes the four weeks you spend at the 2.5 mg starter dose — roughly 8% of a first year. Ten of your first twelve months are spent at or near a maintenance dose, which is why every figure here is stated at 10 mg and why the first-year column exists.

The short version of best month-to-month tirzepatide plans

Price the dose you expect to hold, not the one in the advertisement. Add every recurring fee. Verify the pharmacy. Everything else on this page is detail underneath those three.

Done properly the answer is usually one of a handful of programmes: the cheapest verified route runs $215 a month all-in, about $2,580 across a first year including titration.

The next step that actually moves things

Send two or three programmes the same five questions: total at 10 mg including every fee, which pharmacy, is the prescriber licensed in my state, what notice to cancel and what is refundable, and which form of the active ingredient is used.

Whoever answers all five in writing has told you more than any comparison table can, this one included. Whoever does not has also told you something.

One thing worth doing annually

Re-price the market at your actual maintenance dose. No programme notifies existing patients when a competitor drops below it, and tirzepatide pricing moved repeatedly through 2025 and 2026 — manufacturer cuts, an oral option, a higher-dose product, and several platforms leaving compounded entirely.

An hour once a year is a poor use of time for most purchases and an excellent one for a medication you may take for years.

Reading this alongside the rest of the site

Pricing pages isolate one component. Provider reviews carry the whole record for one programme. Comparisons run two side by side at every dose. The rankings sort the same dataset on different questions. None is the whole picture and none is meant to be.

If you read one other page, make it how to verify a pharmacy. Price is the easiest thing to compare and rarely the thing that goes wrong.

What we would need to change our mind

A programme publishing a figure at a dose tier currently blank. A named dispensing pharmacy with a checkable licence. A pricing model changing in either direction. A regulatory action. Or a correction from a reader with a source we can open.

All five are logged with the date they landed, on the change log and in the dataset. Prices here were captured 2026-08-05.

What this site will not do

Publish an estimated price for a programme that does not publish one. Rank a programme higher because it pays. Present a compounded preparation as equivalent to an approved product. Or carry a figure without the date it was captured.

Those four rules cost us pages, rankings and revenue, and they are the only reason a reader has to prefer this to a round-up assembled in an afternoon. A price without its date is not a fact, and a comparison built from undated prices is not a comparison.

Who this site is not for

Anyone with coverage under a documented indication, who should use it rather than read a cash comparison. Anyone looking for a source without a prescription, which this site will not help with. And anyone wanting a single confident recommendation, because the honest answer depends on your dose, your coverage and your tolerance for commitment.

If you want the short version anyway: price the dose you will hold, add every fee, verify the pharmacy, and avoid long prepaid terms until you have tolerated a maintenance dose for a cycle.

What the GIP arm may be doing

GIP receptor agonism is the pharmacological difference between tirzepatide and the GLP-1-only agents, and its contribution is still being characterised. Proposed mechanisms include effects on adipose tissue insulin sensitivity, on central appetite pathways distinct from the GLP-1 route, and on the tolerability of GLP-1 agonism itself, which would allow effective exposure at doses that would otherwise be poorly tolerated.

This is an area of active research rather than settled science, and anyone stating the mechanism confidently is ahead of the literature. What is established is the outcome difference in the head-to-head trial; the explanation for it is not fully resolved.

The question worth asking before the price question

Whether you have a covered indication. Tirzepatide is approved for chronic weight management and, as Mounjaro, for type 2 diabetes; obstructive sleep apnoea in adults with obesity is an additional route. A covered prescription under a documented indication beats every cash route on this site, frequently by an order of magnitude.

Most people do this backwards: compare cash prices, enrol, then discover an indication they already qualified for. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison table on this site will save you.

Reading a price like a clinician would

A clinician deciding whether a programme is workable asks three questions a price comparison usually skips. Can this patient stay on it long enough to reach a maintenance dose? Is the supply reliable enough that titration will not be interrupted? And is the prescriber reachable when the fourth-week nausea arrives?

Each maps to something checkable before enrolling. Long prepaid terms answer the first badly if money is tight. A single owned dispensing facility answers the second worse than several named partner pharmacies, because a programme with one supply route cannot reroute your prescription. And the care model answers the third: asynchronous messaging is adequate for most titration questions and inadequate for a few.

None of that appears in an advertised price, and all of it decides whether the price you chose is the price you end up paying.

What stopping does, and why it belongs in a cost calculation

The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.

Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.

Why the same molecule sells across a fifteenfold range

The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.

That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.

What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.

The pharmacology behind the fees

Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.

A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.